Drug intelligence / Profile preview

IL1RAP-mut CAR-T

Development stage: Preclinical
Lead developer: City of Hope
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IL1RAP-mut CAR-T is a chimeric antigen receptor (CAR) T-cell construct featuring a mutated version of the interleukin-1 receptor accessory protein (IL1RAP) binding domain. It was developed by researchers at the City of Hope National Medical Center as a negative control for IL1RAP-targeting CAR-T therapies in the treatment of acute myeloid leukemia (AML). Unlike the functional IL1RAP CAR-T, which targets IL1RAP-expressing AML blasts and leukemic stem cells, the mutated version lacks specific antileukemic activity, serving to validate that the therapeutic effects of the wild-type CAR-T are mediated through specific antigen recognition.

Other names: IL1RAP-mutated CAR-TIL-1RAP-mutated CAR-TIL 1RAP-mutated CAR-T

Beyond the preview

Go deeper on IL1RAP-mut CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL1RAP-mut CAR-T.

Explore the full profile